EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical and Molecular Evolution During Panitumumab-Containing Therapy in EGFR-Amplified Esophagogastric Adenocarcinoma

Devyn T Coskey, Kruti B Vora, Yin Guo, Ryan H Moy

The Oncologist · 2026-11-04

DOI: 10.1093/oncolo/oyag440 ↗
AbstractBibliografische Angaben

Abstract

Abstract Esophagogastric adenocarcinoma (EGA) is an aggressive malignancy with limited targeted treatment options. EGFR amplification defines a molecular subset associated with response to EGFR-directed therapy, although mechanisms of resistance remain poorly characterized. We present a 66-year-old man with EGFR-amplified metastatic EGA who achieved a metabolic response on positron emission tomography-CT (PET/CT) during panitumumab-containing therapy, accompanied by loss of detectable EGFR amplification on serial plasma circulating tumor DNA (ctDNA). At progression, repeat tissue biopsy demonstrated HER2 IHC 2+/SISH-positive disease not identified at baseline, and next-generation sequencing identified ERBB2 and KRAS amplifications. These findings suggest ERBB2-mediated bypass signaling as a potential mechanism of resistance to EGFR inhibition, with concurrent KRAS amplification as a possible contributor. It also demonstrates the utility of longitudinal tissue and plasma profiling to capture tumor evolution, identify potential resistance mechanisms, and inform adaptive treatment strategies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →